Access cutting-edge melanoma treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access melanoma specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related melanoma treatment provided free
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone. These types of immunotherapy study drugs are collectively known as immune checkpoint inhibitors. Immunotherapies are treatments that use the immune system to recognize and kill cancer cells. The study is focused on participants with a
Sponsor: Regeneron Pharmaceuticals
Check if you qualify for this melanoma clinical trial in San Francisco, CA
If you're searching for melanoma treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.